摘要
BCR-ABL融合蛋白是慢性髓系白血病(CML)的生物标志物,也是目前针对CML进行药物开发设计的重要靶点。中药砷剂砒霜(As2O3)和雄黄(As4S4)在治疗CML方面具有良好的效果,可通过多种途径诱导细胞凋亡或分化,但砒霜的高毒性和雄黄的难溶性对其临床使用带来极大的困难。本文对目前中药砷剂及新型砷剂雄黄微生物转化液治疗CML的研究和作用机制进行综述,为中药砷剂特别是雄黄的二次开发和应用提供参考。
The BCR-ABL fusion protein is a biomarker of chronic myeloid leukemia(CML),which is currently an important target for drug development and design of CML.TCM arsenic(As2O3)and realgar(As4S4)have been proven to show significantly efficacy in the treatment of CML,which can induce apoptosis or differentiation through many approaches.However,the high toxicity of arsenic and the poor solubility of realgar hamper their clinical application.In this article,the research progress and mechanism of the current TCM arsenic and a novel arsenic agent,realgar transforming solution in the treatment of CML were reviewed,which could provide references for the secondary development and application of TCM arsenic,especially realgar.
作者
王欣
谭详敏
王梅竹
李红玉
WANG Xin;TAN Xiangmin;WANG Meizhu;LI Hongyu(School of Pharmacy,Lanzhou University,Lanzhou 730000,China;School of Life Sciences,Lanzhou University,Lanzhou 730000,China)
出处
《中国中医药信息杂志》
CAS
CSCD
2020年第6期136-140,共5页
Chinese Journal of Information on Traditional Chinese Medicine
基金
国家自然科学基金(81403145、81560715)
国家科技重大专项-重大新药创制(2015ZX09501-004-008)
中央高校基本科研业务费专项资金(lzujbky-2018-136、lzujbky-2017-206)。
